Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...

Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity. The French biopharmaceutical company said ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of nephropathic cystinosis – a rare, progressive and life-limiting condition ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

Theolytics has named Matilde Saggese as its new Chief Medical Officer, as the Oxford-based biotech company accelerates ...